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Elevation of the serum urate is well recognized as
an invariable side effect of treatment with all diuret-
ics except those agents, such as triamterene and
amiloride, that retain potassium. Practitioners can-
not fail to appreciate the frequency of hyper-
uricemia in many of their patients because, even in
asymptomatic patients, it is regularly brought to
their attention in the various profiles of biochemical
tests. As diuretics are among the most commonly
used drugs, the development of a new drug of this
class that did not cause hyperuricemia, but which
retained many of the other beneficial effects of the
oral diuretics, would seem an advantage and would
be of considerable interest. There is general agree-
ment that diuretic-induced hyperuricemia is due, at
least in part, to increased tubular reabsorption of
urate as part of a generalized increase in reabsorp-
tion of sodium and other substances in the proximal
tubule. This results from the plasma volume con-
traction secondary to the electrolyte and fluid loss
during the diuresis [1-4]. The additional possibility
remains that diuretics may also interfere with some
of the urate secretory or reabsorptive processes
within the kidney, either directly or as a result of
redistribution of blood flow.
Uric acid as a risk factor in disease
Enthusiasm for a diuretic that would not cause or
aggravate hyperuricemia needs to be tempered by
an appreciation of the risks of hyperuricemia, some
of which are well known and others of which are
less well defined. Thus, it is well established that
the incidence of gouty arthritis rises roughly in pro-
portion to the degree of hyperuricemia and that this
risk becomes considerable at serum urate concen-
trations persistently over 0.6 mmoles/liter (10 mgI
dl) [5]. Therefore, patients who have had an attack
of gout present a particular problem when they need
treatment with a diuretic, and a diuretic can some-
times not be used in patients in whom control of
hyperuricemia is difficult.
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It is now generally accepted that asymptomatic
hyperuricemia of moderate degree is not in itself a
justification for drug treatment to lower the serum
urate. Such an acceptance, however, involves an
assessment of the risk of uric acid as a possible con-
tributor to both renal disease and to degenerative
vascular disease [6]. Reports during the nineteenth
century certainly included both renal and vascular
disease as part of the syndrome of gout, but the sug-
gestion that uric acid might contribute to degenera-
tive vascular disease has generally not been sub-
stantiated until recently. The first support was pro-
vided by the listing of hype ruricemia among the risk
factors for coronary artery disease [7, 8], and al-
though such a listing does not imply a causative
relationship, such a relationship was for a time as-
sumed to exist. This problem of interpretation
arises from the fact that hyperuricemia is often an
associated feature of several other vascular risk fac-
tors, particularly hypertension, obesity, and hyper-
triglyceridemia. There have been many detailed as-
sessments of this interrelationship [9], the most im-
pressive being the Coronary Drug Project in USA
[10], which concluded that the association of hyper-
uricemia with vascular disease was secondary to
other factors and that hyperuricemia was not in it-
self a primary risk factor. Despite this, however,
there has been a more recent tendency, particularly
among hematologists, to regard hyperuricemia as a
factor that might modify platelet function so as to
increase platelet adhesiveness [11, 12] and thereby
promote atherosclerosis. The Anturan Study [13],
in which a lower incidence of recurrence was ob-
served in patients recovering from myocardial in-
farction who were treated with large doses of sul-
phinpyrazone or anturan, has been taken as indirect
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support for such a thesis. This agent has both a po-
tent uricosuric effect as well as an action to reduce
platelet stickiness. It may well have other additional
actions, and there is still uncertainty about whether
its apparent beneficial effect after myocardial in-
farction is mediated by its effect on uric acid or by
an alternative mechanism such as an antiarrhythmic
action. In summary, although there is some current
evidence to suggest that hyperuricemia may pro-
mote degenerative vascular disease, this is far from
conclusive.
There is also relatively little hard data concerning
the risk of developing renal disease related to uric
acid. We know that there are at least two mecha-
nisms whereby uric acid can induce renal damage
[14]. The first occurs when uric acid is deposited
within the renal tubules causing tubular obstruction
and subsequent nephron dysfunction. This is often
reversible by an early, intense alkaline diuresis and
is presumably related to the concentration of uric
acid in, and the pH of, the tubular fluid. The second
mechanism by which uric acid can induce renal
damage is by the deposition of monosodium urate
crystals within the renal interstitium with a resulting
foreign body reaction and the formation of an inter-
stitial microtophus. There is evidence that in some
cases this lesion may develop from a uric acid de-
posit that was originally intratubular [15, 16]. It may
also develop in situ in the interstitium of the kidney
if local concentrations of urate are appropriate or if
there is a deficiency of inhibitors of urate crystalli-
zation. We also know that this interstitial micro-
tophus formation may occur in the kidney of pa-
tients who have never suffered from gouty arthritis
and that it is a not uncommon finding at autopsy if it
is carefully sought. We have a local series of over 70
such cases, and a search of their records has in-
dicated that the major positive correlation of inter-
stitial microtophus formation was with preexisting
renal disease. We also know that occasional pa-
tients with normal renal function may develop renal
insufficiency when given uricosuric drugs and that,
once again, this can often be reversed by an alkaline
diuresis. We presume that it is caused by uric acid
crystal deposition in the tubules and that it should
be preventable by a sufficiently good urine flow rate
or adequate alkalinization of the urine. When it
does occur, it is likely to occur during the first few
days of uricosuric treatment when the outpouring of
uric acid in the urine is greatest.
Thus, in our stage of incomplete knowledge con-
cerning the factors that can induce renal damage
from uric acid, it is difficult to be too strongly reas-
suring that a high concentration of uric acid, either
in the blood or in the urine, is of no consequence as
far as renal function is concerned. The incidence of
renal disease secondary to primary gout is quite sig-
nificant, and occasional patients who have never
suffered from gouty arthritis have been found to
have renal microtophi on biopsy or at autopsy.
Thus, although one does not regard uric acid as an
important factor in the induction of renal disease,
one has to accept that there is, at least, some poten-
tial risk and that it would be better if its concentra-
tion in body fluids was no higher than avoidable.
Uricosuric diuretics. There are only two un-
cosuric diuretics developed to a stage where they
have been administered to man. Both are phe-
noxyacetic acid derivatives and, as such, are chem-
ically most closely related to ethacrynic acid. Of the
two, ticrynafen or tienylic acid is the more potent
uricosuric agent and is already marketed in the
USA.' The other agent, indacrinone, appears to
have a different mode of action and shows some dis-
tinctive features. In man, it is less potently un-
cosunic than is ticrynafen, and its ultimate role
seems more likely to be as an agent that does not
affect the serum urate concentration either by in-
creasing it or reducing it, rather than as one which
positively corrects hyperuricemia.
Ticrynafen
Ticrynafen or tienylic acid is the most potent un-
cosuric diuretic available. In doses of 250 mg, the
diuretic effect is comparable to that of 500 mg of
chlonothiazide, between 25 and 50 mg of hydro-
chlorothiazide, 25 mg of chlorthalidone or 50 mg of
ethacrynic acid [17]. It has a relatively long duration
of action, being maximal within 4 hours of adminis-
tration with a slight residual effect persisting to 24
hours.
Site and mode of action. During a water diuresis,
ticrynafen causes an increase in osmolar clearance
but a reduction in free water clearance, and urine
volume does not change significantly. During hy-
dropenia, however, free water reabsorption either
After this review was prepared, ticrynafen was withdrawn
from the market in the USA because of an unexpectedly high
incidence of hepatic toxicity. There is no evidence that this is
related to either the diuretic or uricosuric action of the drug. Be-
cause of the extensive basic and clinical pharmacology that has
been summarized in the present review, and because such stud-
ies will undoubtedly be useful both in the evaluation of basic
mechanisms and in the development of other uricosuric diuret-
ics, the review has been published in otherwise unmodified form.
[Editorl
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Table 1. Short-term effects of ticrynafen, pyrazinamide, probenecid, and combinations of these agents on fractional excretion of uratea
Fractional excretion of urate
Control Experimental
Ticrynafen
Pyrazinamide
Probenecid
Ticrynafen + pyrazinamide
Ticrynafen + probenecid
Ticrynafen + probenecid + pyrazinamide
11.2 1.3
10.6 1.3
10.7 1.3"
10.7 1.7
11.6 1.4
11.2 0•9b
47.5 57c
5.1 0.7e
26.0 6•0b
13.3 5.0
66.4 2.6
19.6 4.0"
a Data is from Ref. 21. Control is the mean SEM of values during three control 20-mm collections. Experimental is the mean SEM of
values during experimental 20-mm collections during the 4th hour after medicationp < 0.05.
P < 0.005.
rises slightly or is unchanged. This indicates that
the major site of its natriuretic action is in the cor-
tical diluting segment of the distal tubule [18, 19]
and suggests a mode of action similar to the thiazide
diuretics rather than to that of ethacrynic acid to
which it is chemically related. Thus, ticrynafen ex-
hibits a natriuretic ceiling similar to the thiazide
group. As a uricosuric agent, it produces a consid-
erable increase in urinary uric acid during the first
few days of treatment, which steadily declines, so
that, with prolonged therapy, there is only a moder-
ate increase in uric acid excretion over that in a con-
trol period. Accordingly, any risk of uric acid crys-
tal deposition within the renal tubules would be
maximal during the first few days of treatment. Be-
cause the uricosuric response is more intense than
the diuretic response is, it is important to ensure
that a good urine flow rate is maintained during this
time. Studies with pyrazinamide (which, at the
doses used, chiefly blocks tubular secretion of
urate) strongly suggest that the uricosuric action of
ticrynafen is due to inhibition of reabsorption, both
of filtered urate as well as of urate that is secreted
into the renal tubule [20]. It is believed that this in-
hibition of reabsorption occurs at presecretory as
well as at postsecretory sites (Table 1) [21]. The ex-
tent of the uricosuria is dose related, and the ef-
fective uricosuric dose is lower than the dose which
will produce an effective antihypertensive or diuret-
ic action. The uricosuria induced by 250mg of ticry-
nafen is greater than that induced by 500 mg of
probenecid, and the uricosuria induced by a combi-
nation of these two drugs is greater than that in-
duced by either alone (Table 1). The uricosuric effect,
both alone and with probenecid, is reduced by pyra-
zinamide but still remains greater than it is in the
control period. The uricosuria is also reversed by
aspirin. There is no evidence that ticrynafen affects
urate production or extrarenal elimination. Xan-
thine oxidase is not inhibited.
Ticrynafen also induces an increase in net acid
excretion, and there is a regular fall in urinary pH
[18]. There is also an overall reduction in urinary
calcium excretion and an increase in urinary magne-
sium and phosphate excretion [20]. As might be ex-
pected from the mode of action being similar to the
thiazide diuretics, there is a tendency for the serum
sodium and potassium to fall. Similarly, there is
controversy concerning whether the hypotensive
action of ticrynafen is fully explicable by the associ-
ated loss of salt and water induced by the diuresis.
Preliminary evidence in dogs in which the equiva-
lent of the urinary losses of salt and water were re-
placed intravenously suggest a direct hypotensive
effect unrelated to the diuresis [22].
The drug has been extensively studied in man.
Single doses induce an appreciable diuresis for be-
tween 4 and 8 hours. A particular dose will give a
more prolonged diuresis if it is given in divided frac-
tions at intervals, for example, 60 mg second hourly
on four occasions will give a more prolonged diure-
sis than will 250 mg administered on one occasion
[23]. In short-term studies in man, the serum urate
falls within an hour, reaches a minimum at about 8
hours at a value of between 50 and 75% of the pre-
treatment value, and returns close to normal values
within 24 hours. The fact that the uricosuric re-
sponse is the same to a single dose as it is to four
quarter doses suggests that the uricosuric effect is
not dependent on the plasma concentration of the
drug.
Absorption, bioavailability, and protein binding.
There is a moderate variation in the bioavailability
of the drug with evidence of a 2.5-fold range [23].
Absorption is rapid and plasma concentrations be-
tween 15 and 30 g/ml are achieved within an hour.
The drug is strongly protein-bound, with greater
than 99% bound in vitro at therapeutic concentra-
tions. There appears to be one principal binding site
of high affinity to serum proteins [23]. Accordingly,
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filtration of the drug at the glomerulus is negligible.
The drug is metabolized in the liver to two principal
metabolites, the hydroxy metabolite and the diacid
metabolite. Excretion of both drug and metabolites,
however, appears to be largely via the kidney,
where elimination is complete within about 48
hours. There is an elimination t'/2 of about 2.8
hours.
Excretion. As it is so strongly protein-bound, ti-
crynafen must reach the tubule from the antiluminal
side, and as such, it must be secreted into the tu-
bule. Increasing the pH of the urine increases the
clearance of ticrynafen considerably. In the dog, a
fall in the U/P ratios of ticrynafen to creatinine
along the nephron indicates that there is progressive
reabsorption of the drug along the renal tubule. It is
concluded that there is active secretion of ticryna-
fen in the proximal tubule with passive pH-depen-
dent reabsorption along the rest of the nephron [24].
It seems that ticrynafen most likely enters the lu-
men through the common organic acid pathway.
Para-aminohippurate (PA H) is found to depress its
transport in the proximal tubule and, conversely, ti-
crynafen also interferes with PAH transport in the
proximal tubule. Ticrynafen also reduces the excre-
tion of penicillin, pyrazinamide, and phenolsulfo-
nephthalein (PSP). It seems, therefore, that its
transport via the common organic acid pathway in-
volves a carrier that has a higher affinity for ticryna-
fen than for PAH.
Interactions. The major interaction of the drug is
most likely to be associated with the oral anti-
coagulants because of its high protein-binding affini-
ty and the anticipation that protein-binding dis-
placement might occur between ticrynafen and oth-
er anionic drugs. Although direct tests involving the
addition of ticrynafen did not show an effect on the
serum protein binding of warfarin [25], it is general-
ly recommended that the drug not be used in con-
junction with oral anticoagulants.
Complications. Side effects of the drug have been
relatively few. As high doses have been ototoxic in
cats and guinea pigs, its use in very high dosage or
in renal failure should be monitored by plasma lev-
els. No effect on hearing, however, has been dem-
onstrated in man. The acute falls in the serum urate
concentration that occur might be expected to pre-
cipitate acute attacks of gout but this has not been a
frequent development. The chief problem has been
the development in a few patients of an episode of
acute reversible renal insufficiency, the incidence
being assessed as about 1 in 50,000 cases [26].
When it occurs, this has tended to be seen after the
first or the second dose and has shown up either as a
reduction in urine volume or with transient renal in-
sufficiency, with or without a dull lumbar pain [27].
All features have reversed when the drug has been
ceased or when a diuresis has been induced. The
significance of this finding is a most important one
that needs further elucidation. Its most likely cause
is either an acute tubular dysfunction [27], tubular
obstruction from uric acid crystals or an acute inter-
stitial nephritis, such as occurs with a wide variety
of drugs including allopurinol. When this side effect
develops, it is difficult to assess the specific etiology
in an individual patient because of our limited un-
derstanding of many of the factors that can induce
uric acid crystal formation within the renal tubules.
Accordingly, it is now recommended that the drug
should not be given to a dehydrated patient (or one
who has been on another diuretic during the preced-
ing few days) or to one who cannot maintain a good
urine volume [27]. Only further experience will tell
whether such preventive measures are sufficient to
eliminate this side effect. Assessment of whether an
acute interstitial nephritis has occurred is just as dif-
ficult because, even when renal biopsy evidence of
this is available, there is usually no comparative his-
tology prior to use of the drug and the patient has
often been on other therapeutic agents that could
themselves have caused such an interstitial nephri-
tis. Those who use the drug, however, should be
alert to these possibilities. It should be added, how-
ever, that the risk of inducing uric acid crystal depo-
sition within a tubule should be less with a un-
cosuric diuretic than it would be with a uricosuric
drug that is not a diuretic. Studies have shown that
the use of ticrynafen is not associated with an in-
crease in the degree of urinary supersaturation for
uric acid or monosodium urate [28]. If this is cor-
rect, it makes it even more difficult to interpret
these occasional serious reactions involving the kid-
ney. One must also bear in mind, however, the in-
creased acid excretion induced by the drug, and this
may be one of the variables that contributes to any
intratubular crystal deposition. It should be remem-
bered, however, that more ticrynafen will be reab-
sorbed from the tubular lumen as the pH of the
tubular fluid falls, and as the uricosuric response ap-
pears to be related to the concentration of ticryna-
fen in the tubular fluid [29], so there should be a
lessening of the uricosuria with increasing acidity of
the urine. Such increasing acidity would be associ-
ated with an increased tendency to intraluminal uric
acid precipitation.
Clinical use. Ticrynafen has had extensive clini-
cal use prior to its release in the USA. A dose of 250
mg a day is effective in causing a fall in blood pres-
sure, a fall in the serum urate concentration, and
effects on sodium, potassium and chloride very sim-
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ilar to those of the thiazide diuretics. As shown in a
recent large Veterans Administration study of the
treatment of hypertension [30], there is a tendency
for a greater elevation of the serum creatinine
concentration with ticrynafen than with hydro-
chiorothiazide, but both of these effects reverse on
withdrawal of the drug. It is of particular interest
that simultaneous frusemide has an additive diuretic
effect, whereas hydrochlorothiazide does not have
any such additive effect [17], thereby providing fur-
ther support for a different site for the diuretic ac-
tion of the two drugs. As a uricosuric, the response
at lower doses is dose-related. Uricosuria is appar-
ent with a dose of as little as 50 mg, which has no
appreciable diuretic effect [17]. In acute studies, the
uricosuric effect increases as the doses rise to 250 or
500 mg per day. In the large Veterans Administra-
tion study of patients with hypertension [30], there
was, however, no greater fall in serum urate with a
dose of 500 mg than with a dose of 250 mg, so that
the potential for considerable uricosuria by progres-
sive increase in dose appears to be limited. The si-
multaneous administration of hydrochlorothiazide
or frusemide does not overcome the uricosuria. In
one study [31], a fall of the serum potassium was
noticed with 6 weeks of treatment with ticrynafen, a
rise in serum potassium with comparable treatment
with propranolol, and no net effect on serum potas-
sium when the combination of ticrynafen and pro-
pranolol was administered. As a hypotensive agent,
it is comparable with hydrochlorothiazide [32], and
the hypotensive effect is additive to that of beta
blockers. Its special therapeutic value is most likely
to be as an adjuvant hypotensive agent in persons
who are already hyperuricemic or who have suf-
fered from gout.
There is relatively little information concerning
its use in significant renal insufficiency, that is, at a
serum creatinine concentration greater than 0.2
mmoles/liter. Like the thiazides, the response be-
comes less with increasing renal insufficiency. The
need for a uricosuric diuretic, however, is particu-
larly great in patients with renal insufficiency, and
we are currently studying the kinetics of the drug in
this situation and the pharmacodynamic response.
As with hydrochiorothiazide, there is a transient
but appreciable increase in the serum creatinine and
urea concentrations [32, 33], but to-date we do not
have sufficient information to make a direct com-
parison between these two drugs.
Indacrinone
The second uricosuric diuretic, indacrinone, a
phenylindanyloxyacetic acid, was originally re-
ferred to as MK-196. It has been a more recent de-
velopment than ticrynafen, and there have been
fewer studies of its action in man. Regarding its site
of action, studies in the rat demonstrated depres-
sion of both net solute-free water excretion and wa-
ter reabsorption and were therefore interpreted as
indicating that its major diuretic action occurred in
the loop of Henle and the collecting ducts [34]. Mi-
cropuncture studies [35] showed that sodium and
water reabsorption was unchanged in the proximal
tubules, and there was no effect on transport in the
distal tubule, whereas reabsorption was markedly
inhibited between the late proximal and early distal
micropuncture sites, namely the loop of Henle. If
similar conclusions are reached from studies in
man, it will indicate quite a different site of action
for this compound from ticrynafen and will suggest
that its mode of action will be more like frusemide
than chlorothiazide.
The uricosuric effect has been attributed to inhi-
bition of reabsorption and secretion of urate in the
proximal tubule [34, 36], the net effect being an in-
crease in urate excretion. Its uricosuric action has
been extensively studied in the chimpanzee [37],
which, despite some significant differences, is prob-
ably as close an animal model as one can get to man
in regard to renal handling of urate. These studies
showed a fivefold to sevenfold increase in the urate
clearance in relation to the GFR. Indacrinone over-
comes the urate retention induced by pyrazinamide,
and pyrazinamide only slightly reduces the un-
cosuria due to indacrinone. This is in contrast to the
effect of probenecid, the uricosuria of which is con-
siderably reduced by pyrazinamide. Pyrazinamide
has no effect on the diuretic action, again empha-
sizing the disparity between the diuretic and the un-
cosuric effects of the drug. No effect has been dem-
onstrated on phosphate excretion, and this absence
of any effect on the excretion of another substance
that is transported in the proximal tubule suggests
strongly that the uricosuric action is not part of a
generalized effect on proximal tubular transport,
but rather a specific one on urate transport alone.
This is further supported by the finding that the drug
has no effect on proximal tubular transport of so-
dium. There is, however, an increased excretion of
both calcium and magnesium, which has been at-
tributed to inhibition of their reabsorption at a distal
site.
Absorption, protein binding, and metabolism. In-
dacrinone is well absorbed from the alimentary
tract, and peak plasma levels are achieved within an
hour in both animals and man. Like ticrynafen,
more than 99% is strongly bound to protein. Its me-
tabolism differs in different species, but its major
metabolite appears to be derived from para-hy-
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droxylation of the phenyl moiety, with subsequent
methylation. There appears to be minimal, if any,
glucuronide formation in man. The peak plasma
concentration of metabolite occurs at between 4
and 6 hours after administration.
Excretion. Although its excretion appears to be
chiefly by the fecal route in the rat and dog [38,
39], the major route of excretion in both man and
the chimpanzee appears to be by the kidney. The
pattern of elimination is similar to that of other
weak organic acids and ticrynafen in that it is se-
creted by the proximal tubule (a process strongly
inhibited by probenecid and a high PAH load) and
passively diffuses back across the tubular epithe-
hum by a pH-dependent process. Alkalinization of
the urine increases its excretion by up to ten times.
In man, 50% of a dose of the labeled drug is ex-
creted in the urine, mostly in the first 24 hours, and
another 40% is excreted in the feces. Of that ex-
creted in the urine, 25% appears as indacrynone and
70% as metabolites, the excretion of the metabolites
being somewhat slower than that of the parent com-
pound.
Clinical use. Indacrinone appears to be inter-
mediate between a short-acting diuretic such as
frusemide and a longer acting diuretic such as hy-
drochiorothiazide in relation to time of onset of
maximum activity and the duration of diuretic activ-
ity. Most of its activity occurs within 8 hours, and a
10-mg dose is comparable with 40 mg of frusemide
or 50 mg of hydrochiorothiazide. Repeated daily ad-
ministration for up to 2 weeks has shown sustained
but barely significant increases in saluresis over the
control excretion. The increases in urinary urate
that occurred were not significant, and there was no
significant change in the serum urate concentration.
It has an effective antihypertensive action. As well
as being uricosuric, it promotes the renal excretion
of potassium, calcium, and magnesium but does not
alter phosphate excretion. Potassium supplements
may be needed.
Dose-response study. Initial studies in human
volunteers indicated that, although a 10-mg dose
was both diuretic and uricosuric, it had relatively
little sustained effect on the serum urate concentra-
tion. We therefore looked at the question of the
dose-response relationship of indacnnone in healthy
subjects to determine whether larger doses of the
drug would have a greater uricosuric effect without
there necessarily being an equivalent increase in the
diuretic action [40]. Thus, in volunteers under stan-
dardized conditions, the response to different doses
of the drug was compared with excretion rates dur-
ing a control period and compared with the response
to frusemide. The changes that occurred after its
administration in the rate of excretion of sodium
and urate in comparison with the preceding control
day, at intervals of 0 to 6 hours, 6 to 12 hours and 12
to 24 hours, are shown in Figs. 1 and 2. There was
a progressive dose-dependent increase in urine flow
rate and in the urinary excretion of sodium, potas-
sium, and urate with doses of indacrinone between
20 mg and 80 mg. The natriuretic response to the
20-mg dose was comparable with that to 40 mg of
frusemide but was of significantly greater duration
at each of the dose levels tested. Urate excretion
Fru semide
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Fig. 1. Mean changes (+sD) in urinary sodium excretion rate of healthy volunteers at various time intervals on the day of treatment with
indacrinone or frusemide, in comparison with the control day. (Reproduced from Emmerson et al [40] with permission of Plenum
Publishing Corporation)
Uricosuric diuretics 683
(Fig. 2), however, was of particular interest be-
cause, whereas frusemide caused an invariable
reduction in urinary urate excretion at all time in-
tervals, indacrinone induced an appreciable un-
cosuria during the first 6-hour period but a reduc-
tion in urate excretion in the remainder of the
24-hour period of observation. The overall effect
resulted in no net change in urinary urate excretion.
Such a biphasic response is of considerable interest
and could be due either to the paradoxical effect
of different concentrations of the drug on net renal
excretion of urate or to a response to the plasma
volume contraction resulting from the diuresis,
which results in an increase in proximal tubular
reabsorption of urate leading to a reversal of the
primary uricosuric effect. Weight loss occurred
with the diuretic effect, resulting in an average loss
of 0.9 kg at a 20-mg dose, 1.4 kg at the 40-mg dose,
and 2.2 kg at the 60- and 80-mg dose. There was no
significant fall in the standing blood pressure, al-
though postural hypotension was seen occasionally.
The pulse rate, however, did rise and consistently
reached a peak between 12 and 24 hours after ad-
ministration of the drug (Fig. 3), and this may well
be a reflection of a reduced circulating plasma vol-
ume. Certainly, a rise in the serum urate tends to
parallel and follow the rise in the pulse rate, and it
may be that, at this time, the uricosuric effect is not
sufficiently great to overcome the urate retention in-
duced by the plasma volume contraction resulting
from the diuresis. Further studies with replacement
of the losses of salt and water have not been under-
taken, so that the precise mechanism of this rever-
sal of the unicosuric effect has not been determined.
Combination with amiloride. Our subsequent
studies, again in healthy volunteers, have been di-
rected towards a different question, namely the as-
sociated increase in the excretion of potassium and
the fall in urine pH. On this occasion, a dose of 10
mg of indacrinone was used, which gave a response
comparable with that of 40 mg of frusemide or 50
mg of hydrochlorothiazide. Its effect was studied in
12 healthy subjects by comparing, in random order,
the response to a placebo, to a 10-mg dose of in-
dacrinone, and to the addition to this dose of in-
0. I ndacrinone
20mg 40mg
Frusemide
40mg
0
0.1
0
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Fig. 2. Mean changes (+ SD) in urinary urate excretion rate of
healthy volunteers at various time intervals on the day of treat-
ment with indacrinone orfrusemide, in comparison with the con-
trol day. (Reproduced from Emmerson et a! [40] with permission
of Plenum Publishing Corporation)
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dacrinone of either 2.5 or 5 mg of the potassium-
retaining agent amiloride. This dose of indacrinone
produced a significant diuresis and natriuresis,
which were not affected significantly by the addition
of either dose of amiloride. Again, uricosuria was
demonstrated during the first 4-hour period and
slight urate retention during the 12- to 24-hour peri-
od; there was minimal net effect on the serum urate
concentration. The addition of 2.5 mg of amiloride
reduced potassium excretion to levels not signifi-
cantly different from those in the control period. In-
dacrinone alone caused a considerable fall in urine
pH, which was greatly reduced (although not quite
to that of the control period) by the addition of 2.5
mg of amiloride. It seems, therefore, that the addi-
tion of 2.5 mg of amiloride to a 10-mg dose of in-
dacrinone results, in normal subjects, in the correc-
tion of the associated kaluresis and the fall in urine
pH. Correction of this latter feature may be of par-
ticular significance in view of the associated un-
cosuria, in which the increased urinary uric acid ex-
cretion would otherwise occur into an increasingly
acid urine.
More recent studies of indacrinone have shown
that apparently minor variations in its structure can
produce important alterations in its pharma-
codynamic responses. It is therefore possible to
produce a number of compounds with a wide range
of uricosuric/diuretic ratios. For a given diuretic ef-
fect, some of these compounds exhibit a lesser un-
cosuric effect, whereas others may have a greater
uricosuric response. Alternatively, if the uricosuria
is the desired response, a variety of diuretic re-
sponses can be developed. In particular, it has been
realized that the parent compound, indacrinone, is a
racemic mixture of two enantiomorphs, each with
apparently different uricosuric/diuretic activities,
and each individually different from the racemate
(Jeremy, personal communication). The positive
enantiomorph is potently uricosuric and only mod-
erately natriuretic, whereas the negative enanti-
omorph has a greater natriuretic action but a much
smaller uricosuric action. Such a finding provides
the potential for varying the ratios of the two enan-
tiomorphs to produce a compound that will have a
wide range of uricosuric/diuretic ratios.
Summary. Two new diuretics have been devel-
oped that promote renal excretion, rather than re-
nal retention, of urate. Both ticrynafen and in-
dacrinone are phenoxyacetic acid derivatives and
are chemically related to ethacrynic acid. Both
cause uricosuria, probably by inhibiting reabsorp-
tion of filtered as well as of secreted urate. As well
as causing natriuresis and chloruresis, both pro-
mote excretion of potassium, hydrogen, and magne-
sium ions. Both are strongly protein-bound, and
both appear to enter the renal tubule by active se-
cretion via the common organic acid pathway,
which can be blocked by PAH. Within the tubule,
they are reabsorbed by a passive pH-dependent
process, which is reduced by alkalinization of the
urine. The extent of the uricosuria appears to be re-
lated to the concentration of the drug in the urine.
There also appear to be some distinctive features.
In man, ticrynafen appears to exert its diuretic ef-
fect by an action on the cortical diluting segment of
the distal tubule. This is similar to that of the thia-
zides, and frusemide has an additive diuretic effect,
thereby suggesting a different site of action in the
nephron. The diuretic action of indacrinone, by
contrast, appears to lie in the ascending limb of the
loop of Henle in the rat, but has not been precisely
defined in man. In this, it seems more like frusemide
itself. Ticrynafen has a potent uricosuric effect in
man, and its use has rarely been associated with
transient renal insufficiency, which has reversed on
stopping the drug. This has been attributed to uric
acid crystal deposition within the renal tubules, but
alternative explanations are possible. Its use should
be avoided in dehydrated patients or those with a
persistently acid urine. Indacrinone by comparison
appears to resemble the high-ceiling diuretics in
man, and increasing doses show an increasing diu-
retic and uricosuric effect. In healthy subjects, the
initial uricosuria of indacrinone lasts only about 6
hours and is followed by urate retention, so that
there is minimal resultant change in the plasma
urate concentration. The concomitant administra-
tion of amiloride with indacrinone abolishes the in-
creased excretion of hydrogen and potassium ions.
Both agents promise to provide a useful extension
of our current diuretic and antihypertensive thera-
py.
Reprint requests to Prof. B. T. Emmerson, Department of
Medicine, Princess Alexandra Hospital, lpswich Road, Brisbane
4/02, Australia
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